Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49(1):13–23. doi:10.1016/j.lungcan.2005.01.002
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–3559. doi:10.1200/JCO.2007.13.9030
   PubMed Web of Science ®Google Scholar
• Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable NSCLC. J Clin Oncol. 2001;20:247–253.
   Google Scholar
• Paz-Ares L, Corral J. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–1571.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized Phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30(2):172–178. doi:10.1200/JCO.2010.33.7089
   PubMed Web of Science ®Google Scholar
• Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611–621.
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110–118. doi:10.1373/clinchem.2012.194258
   PubMed Web of Science ®Google Scholar
• Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a Phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18(8):2391–2401. doi:10.1158/1078-0432.CCR-11-3148
   PubMed Web of Science ®Google Scholar
• Muinelo-Romay L, Vieito M, Abalo A, et al. Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers. 2014;6(1):153–165. doi:10.3390/cancers6010153
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904. doi:10.1158/1078-0432.CCR-04-0378
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–928. doi:10.1158/1078-0432.CCR-06-1695
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421. doi:10.1155/2010/617421
   PubMedGoogle Scholar
• Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–1563. doi:10.1200/JCO.2010.28.7045
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791. doi:10.1056/NEJMoa040766
   PubMed Web of Science ®Google Scholar
• Mikolajczyk SD, Millar LS, Tsinberg P, et al. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol. 2011;2011:252361. doi:10.1155/2011/252361
   PubMedGoogle Scholar
• Gires O, Stoecklein NH. Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci. 2014;71(22):4393–4402. doi:10.1007/s00018-014-1693-1
   PubMed Web of Science ®Google Scholar
• Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5(10):773–785. doi:10.1038/nrc1714
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 2012;13(3):189–203. doi:10.1038/nrg3123
   PubMed Web of Science ®Google Scholar
• C W, H H, L L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 2009;4:30–36. doi:10.1097/JTO.0b013e3181914125
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang X, Ge S, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014;5:6594–6602. doi:10.18632/oncotarget.2175
   PubMedGoogle Scholar
• Feng G, Zhang H, Wang DD, Linda L, Lin PP. Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget. 2015;6(29):27049–27064. doi:10.18632/oncotarget.4819
   PubMedGoogle Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221. doi:10.1200/JCO.2007.15.8923
   PubMed Web of Science ®Google Scholar
• Cen P, Ni X, Yang J, Graham DY, Li M. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta. 2012;1826(2):350–356.
   PubMed Web of Science ®Google Scholar
• Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013;31(18):2273–2281. doi:10.1200/JCO.2012.44.5932
   PubMed Web of Science ®Google Scholar
• Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15(22):6980–6986. doi:10.1158/1078-0432.CCR-09-1095
   PubMed Web of Science ®Google Scholar
• Krebs MG, Hou J-M, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012;7:306–315. doi:10.1097/JTO.0b013e31823c5c16
   PubMed Web of Science ®Google Scholar
• Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17(4):827–835. doi:10.1158/1078-0432.CCR-10-0445
   PubMed Web of Science ®Google Scholar
• Decaluwe H, De Leyn P, Vansteenkiste J, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur j Cardio-Thoracic Surg. 2009;36(3):433–439. doi:10.1016/j.ejcts.2009.04.013
   PubMed Web of Science ®Google Scholar
• Song W-A, Zhou N-K, Wang W, et al. Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer-An Updated Meta-Analysis of 13 Randomized Control Trials. J Thorac Oncol. 2010;5:510–516. doi:10.1097/JTO.0b013e3181cd3345
   PubMed Web of Science ®Google Scholar
• Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nuclear Med. 2009;50(Suppl 1):31S–42S. doi:10.2967/jnumed.108.057216
   PubMed Web of Science ®Google Scholar
• Mouillet G, Monnet E, Milleron B, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non–small-cell lung cancer. J Thorac Oncol. 2012;7:841–849. doi:10.1097/JTO.0b013e31824c7d92
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21(9):1752–1759. doi:10.1200/JCO.2003.11.040
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94(8):1099–1106. doi:10.1038/sj.bjc.6603075
   PubMed Web of Science ®Google Scholar
• William N, Pataer A, Kalhor N, et al. Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy. J Thorac Oncol. 2013;8:222–228. doi:10.1097/JTO.0b013e3182774108
   PubMed Web of Science ®Google Scholar
• Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol. 2006;18(6):658–667. doi:10.1016/j.ceb.2006.10.002
   PubMed Web of Science ®Google Scholar
• Pavelka N, Rancati G, Zhu J, et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature. 2010;468(7321):321–325. doi:10.1038/nature09529
   PubMed Web of Science ®Google Scholar
• Pavelka N, Rancati G, Dr Jekyll LR. Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr Opin Cell Biol. 2010;22(6):809–815. doi:10.1016/j.ceb.2010.06.003
   PubMed Web of Science ®Google Scholar
• Lee AJX, Endesfelder D, Rowan AJ, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71(5):1858–1870. doi:10.1158/0008-5472.CAN-10-3604
   PubMed Web of Science ®Google Scholar
• Lerebours F, Olschwang S, Thuille B, et al. Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer. 1999;81(6):854–858. doi:10.1002/(SICI)1097-0215(19990611)81:6<854::AID-IJC3>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar